are the drugs (also known as oral hypoglycemic/antihyperglycemic agents), which are used for treatment of diabetes mellitus. Diabetes mellitus also commonly known as diabetes metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both which is caused by either the pancreas not producing enough insulin or the cells of the body not responding properly to the insulin produced. According to the International Diabetes Foundation (IDF), globally 415 million people are diagnosed with diabetes which is expected to grow to 640 million by 2040. This significant increase in the number of diabetic population is expected to be the prime growth driver for the antidiabetics market in the near future.
This report identifies the
size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Antidiabetics market.
Globally North America dominated the market for antidiabetics in 2015 due to high penetration and adoption of antidiabetics drugs in the medical system of the region coupled with high healthcare expenditures, patient awareness levels and advanced healthcare infrastructure. North America was followed by Europe and Asia-Pacific as the second and third largest markets respectively for antidiabetics in 2015. Demand for Antidiabetics in Asia-Pacific is expected to witness fastest growth in the near future due to increasing diabetic population in the region coupled with increasing awareness and developing medical infrastructure in the region.
This report on global Antidiabetics is segmented on the basis of various types of Antidiabetics, treated disease and market size in various geographical regions.
- On the basis of types of antidiabetics drugs this report classified as follows covering all major types of antidiabetics drugs as follows: Insulin (Rapid acting, Long acting, Premixed, Premixed analog, Short acting, Intermediate acting, Antidiabetics, Alpha-glucosidase inhibitors), Biguanides (Sulphonylureas, GLP-1 agonist, Meglitinides, DPP-4 inhibitors, SGLT – 2, Thiazolodinediones)
- This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for antidiabetics in each of the region.
Sample Companies Profiled in this Report are:
- Boehringer Ingelheim GmbH
- Sanofi S.A.
- Astra Zeneca plc
- Eli Lilly & Co
- Johnson & Johnson
- Novartis Pharmaceuticals AG